Cargando…

Humoral and cellular correlates of a novel immune-related adverse event and its treatment

Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer receiving antiprogrammed death 1 checkpoint inhibitor who developed a delayed-onset visual irAE trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonugunta, Amrit S, von Itzstein, Mitchell S, Mu-Mosley, Hong, Fattah, Farjana, Farrar, J David, Mobely, Angela, Rashdan, Sawsan, Lai, Sunny, Bhai, Salman F, Bermas, Bonnie L, Karp, David, Li, Quan-Zhen, Wakeland, Edward K, Gerber, David E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655605/
https://www.ncbi.nlm.nih.gov/pubmed/34880115
http://dx.doi.org/10.1136/jitc-2021-003585
_version_ 1784612108597460992
author Gonugunta, Amrit S
von Itzstein, Mitchell S
Mu-Mosley, Hong
Fattah, Farjana
Farrar, J David
Mobely, Angela
Rashdan, Sawsan
Lai, Sunny
Bhai, Salman F
Bermas, Bonnie L
Karp, David
Li, Quan-Zhen
Wakeland, Edward K
Gerber, David E
author_facet Gonugunta, Amrit S
von Itzstein, Mitchell S
Mu-Mosley, Hong
Fattah, Farjana
Farrar, J David
Mobely, Angela
Rashdan, Sawsan
Lai, Sunny
Bhai, Salman F
Bermas, Bonnie L
Karp, David
Li, Quan-Zhen
Wakeland, Edward K
Gerber, David E
author_sort Gonugunta, Amrit S
collection PubMed
description Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer receiving antiprogrammed death 1 checkpoint inhibitor who developed a delayed-onset visual irAE treated with corticosteroids. Through assessment of longitudinal biospecimens, we analyzed serial autoantibodies, cytokines, and cellular populations. Months after ICI initiation and preceding clinical toxicity, the patient developed broad increases in cytokines (most notably interleukin-6 (IL-6), interferon-γ (IFNγ), C-X-C motif chemokine ligand 2 (CXCL2), and C–C motif chemokine ligand 17 (CCL17)), autoantibodies (including anti-angiotensin receptor, α-actin, and amyloid), CD8 T cells, and plasmablasts. Such changes were not observed in healthy controls and ICI-treated patients without irAE. Administration of corticosteroids resulted in immediate and profound decreases in cytokines, autoantibodies, and inflammatory cells. This case highlights the potential for late-onset changes in humoral and cellular immunity in patients receiving ICI. It also demonstrates the biologic effects of corticosteroids on these parameters. Application of humoral and cellular immune biomarkers across ICI populations may inform toxicity monitoring and management.
format Online
Article
Text
id pubmed-8655605
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86556052021-12-27 Humoral and cellular correlates of a novel immune-related adverse event and its treatment Gonugunta, Amrit S von Itzstein, Mitchell S Mu-Mosley, Hong Fattah, Farjana Farrar, J David Mobely, Angela Rashdan, Sawsan Lai, Sunny Bhai, Salman F Bermas, Bonnie L Karp, David Li, Quan-Zhen Wakeland, Edward K Gerber, David E J Immunother Cancer Case Report Immune-related adverse events (irAE) may affect almost any organ system and occur at any point during treatment with immune checkpoint inhibitors (ICI). We present a patient with advanced lung cancer receiving antiprogrammed death 1 checkpoint inhibitor who developed a delayed-onset visual irAE treated with corticosteroids. Through assessment of longitudinal biospecimens, we analyzed serial autoantibodies, cytokines, and cellular populations. Months after ICI initiation and preceding clinical toxicity, the patient developed broad increases in cytokines (most notably interleukin-6 (IL-6), interferon-γ (IFNγ), C-X-C motif chemokine ligand 2 (CXCL2), and C–C motif chemokine ligand 17 (CCL17)), autoantibodies (including anti-angiotensin receptor, α-actin, and amyloid), CD8 T cells, and plasmablasts. Such changes were not observed in healthy controls and ICI-treated patients without irAE. Administration of corticosteroids resulted in immediate and profound decreases in cytokines, autoantibodies, and inflammatory cells. This case highlights the potential for late-onset changes in humoral and cellular immunity in patients receiving ICI. It also demonstrates the biologic effects of corticosteroids on these parameters. Application of humoral and cellular immune biomarkers across ICI populations may inform toxicity monitoring and management. BMJ Publishing Group 2021-12-07 /pmc/articles/PMC8655605/ /pubmed/34880115 http://dx.doi.org/10.1136/jitc-2021-003585 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Gonugunta, Amrit S
von Itzstein, Mitchell S
Mu-Mosley, Hong
Fattah, Farjana
Farrar, J David
Mobely, Angela
Rashdan, Sawsan
Lai, Sunny
Bhai, Salman F
Bermas, Bonnie L
Karp, David
Li, Quan-Zhen
Wakeland, Edward K
Gerber, David E
Humoral and cellular correlates of a novel immune-related adverse event and its treatment
title Humoral and cellular correlates of a novel immune-related adverse event and its treatment
title_full Humoral and cellular correlates of a novel immune-related adverse event and its treatment
title_fullStr Humoral and cellular correlates of a novel immune-related adverse event and its treatment
title_full_unstemmed Humoral and cellular correlates of a novel immune-related adverse event and its treatment
title_short Humoral and cellular correlates of a novel immune-related adverse event and its treatment
title_sort humoral and cellular correlates of a novel immune-related adverse event and its treatment
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655605/
https://www.ncbi.nlm.nih.gov/pubmed/34880115
http://dx.doi.org/10.1136/jitc-2021-003585
work_keys_str_mv AT gonuguntaamrits humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT vonitzsteinmitchells humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT mumosleyhong humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT fattahfarjana humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT farrarjdavid humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT mobelyangela humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT rashdansawsan humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT laisunny humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT bhaisalmanf humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT bermasbonniel humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT karpdavid humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT liquanzhen humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT wakelandedwardk humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment
AT gerberdavide humoralandcellularcorrelatesofanovelimmunerelatedadverseeventanditstreatment